Catalog Advanced Search

News

BioGenex introduces new miRNA probes for cancer diagnosis

16 Sep

BioGenex, a global market leader and an innovator in providing customer-centric molecular pathology solutions, announces the launch of nine new microRNA (miRNA) probes for cancer diagnosis. miRNAs possess several features that make them attractive diagnostic biomarkers. Their small size and improved stability in formalin-fixed paraffin-embedded (FFPE) tissue render them as a superior molecular marker compared to mRNAs, which are prone to extensive degradation in FFPE samples. Our unique miRNA probes enable detection of single nucleotide mismatch, thus allowing high sensitivity and specificity. Over 240 ready-to-use miRNA probes are now available, and more are being developed. BioGenex proprietary Super Sensitive Nucleic Acid (SSNA) miRNA probes are specially designed for in situ hybridization (ISH) of tissue samples. BioGenex miRNA probes have high melting temperatures and are dual-end labeled. Together with BioGenex Super Sensitive Detection kits these SSNA miRNA ISH probes result in a clean and intense stains for localized visualization of key miRNA signal biomarkers. BioGenex ISH system has the ability to generate a robust chromogenic signal while preserving the spatial context of the tissue sample. This provides a powerful tool for precise tumor characterization and a breakthrough for clinical research and analysis of cancer of unknown primary (CUP), poorly differentiated or undifferentiated tumors, and cancer staging.

BioGenex-introduces-new-miRNA-probes

The probes included in the launch are:

Hsa-miR-299-3p:
miR-299-3p has been reported to modulate replicative senescence in endothelial cells and may serve as a potential therapeutic target for clinical use to decrease invasiveness of breast cancer.
Find out more about Hsa-miR-299-3p.

Hsa-miR-301A-3p:
miR-301a-3p expression has been reported to be downregulated in pancreatic cancer cells and may contribute to the development of extrogen independence which leads to a more invasive phenotype of breast cancer.
Find out more about Hsa-miR-301A-3p.

Hsa-miR-556:
miR-556 is a novel marker of human colorectal cancer cells. Expression of miR-556 is important for short disease-free survival and overall survival in stage II colon cancer.
Find out more about Hsa-miR-556.

Hsa-miR-656-3p:
miR-656-3p has been reported to be expressed in colon tissues and was found to be the best predictor of recurrence in TNM-stage II colon cancer patients.
Find out more about Hsa-miR-656-3p.

Hsa-miR-671-3p:
miR-671-3p has been reported to be expressed in colon tissues and function as a tumor suppressor in breast cancer by influencing the WNT signaling cascade.
Find out more about Hsa-miR-671-3p.

Hsa-miR-1537:
miR-1537 has been reported to be upregulated in melanoma and is strongly associated with Her2 molecular subtype of breast cancer. miR-1537 may be used as a diagnostic biomarker for melanoma detection and monitoring.
Find out more about Hsa-miR-1537.

Hsa-miR-4787-3p:
miR-4787-3p is an important marker for breast cancer and can be used for diagnosis of melanoma.
Find out more about Has-miR-4787-3p.

Hsa-miR-5010-3p:
miRNA-5010-3p has been reported to be dysregulated in colon adenomas and can be used as a prognostic biomarker in TNM-stage II colon cancer patients.
Find out more about Hsa-miR-5010-3p.

Hsa-miR-5100:
miR-5100 has been found to be upregulated in patients with non-small-cell lung cancer and pancreatic cancer. miRNA-5100 can also be used to identify high-risk TNM-stage II colon cancer patients. Find out more about Hsa-miR-5100.

Check our miRNA probe page for the entire list of available probes or download our miRNA probe catalog.

BioGenex is offering these new miRNA probes in ready-to-use format in hybridization buffer for 25 test, control slides are also available for all miRNA probes. Our Super Sensitive™ ISH Detection System uses non-biotin polymeric technology to eliminate the inherent biotin contamination and false positive results.
“miRNA in situ visualization  provides a reliable assessment of the physiologic function of miRNA at spatial location and the single-cell level” said  Krishan Kalra Ph.D. CEO of BioGenex.

About BioGenex Laboratories

BioGenex designs develop and commercialize fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. Our fully-automated workstations are the most in-depth systems available globally. Our customer-focused approach, with excellent technical and customer support provides a unique and powerful service for pathology labs. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for Life Science research and diagnostics.

Latest News

Surprice gift